论文信息 - Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients - 字舞流文

Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients

B. Pégourié | C. Sebban | P. Moreau | H. Avet-Loiseau | M. Macro | X. Leleu | G. Marit | J. Corre | T. Facon | F. Guilhot | C. Fruchart | M. Attal | C. Fohrer | L. Garderet | M. Roussel | L. Karlin | A. Stoppa | F. Orsini-Piocelle | S. Bréchignac | C. Hulin | D. Caillot | V. Lauwers-Cances | T. Lamy | G. Lepeu | J. Jaubert | M. Dib | B. Hébraud | M. Dib | J. Fontan | C. Gentil | C. Sohn | T. Lamy | V. Lauwers-Cances

[1] H. Goldschmidt,et al. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project , 2013, Leukemia.

[2] G. Morgan,et al. Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse Survival , 2011, Clinical Cancer Research.

[3] O. Decaux,et al. Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? , 2011, Blood.

[4] G. Morgan,et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. , 2010, Blood.

[5] B. Barlogie,et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review , 2009, Leukemia.

[6] Cheng Li,et al. Prognostic significance of copy-number alterations in multiple myeloma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7] G. Morgan,et al. Deletions of CDKN2C in Multiple Myeloma: Biological and Clinical Implications , 2008, Clinical Cancer Research.

[8] G. Morgan,et al. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. , 2007, Blood.

[9] Michael L. Wang,et al. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10] R. Bataille,et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. , 2007, Blood.

[11] Rafael Fonseca,et al. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. , 2007, Cancer research.

[12] G. Ahmann,et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma , 2006, Leukemia.

[13] D. Reece,et al. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. , 2004, Blood.

[14] R. Bataille,et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. , 2002, Blood.

[15] R. Bataille,et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. , 2001, Blood.

[16] M Schemper,et al. A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.

[17] P. Loehrer,et al. International Staging System for Multiple Myeloma , 2006 .